{
    "ticker": "PALI",
    "name": "Palisade Bio, Inc.",
    "description": "Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on addressing unmet medical needs in the treatment of gastrointestinal (GI) diseases. Founded in 2020, Palisade Bio aims to develop innovative therapies that can significantly improve the quality of life for patients suffering from conditions such as inflammatory bowel disease (IBD), postoperative ileus, and other GI-related disorders. The company's lead product candidate, PB2452, is designed to mitigate the effects of anticoagulants during surgical procedures, enhancing patient safety and recovery. With a robust pipeline of drug candidates targeting various aspects of GI health, Palisade Bio is committed to advancing science and medicine through rigorous clinical research and development. The company employs a multidisciplinary approach, leveraging cutting-edge technologies and a deep understanding of gastrointestinal biology. Palisade Bio's mission is to transform GI treatment paradigms while ensuring patient-centric care, positioning itself as a leader in the biopharmaceutical space.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2020",
    "website": "https://www.palisadebio.com",
    "ceo": "Tom Hallam",
    "social_media": {
        "twitter": "https://twitter.com/palisadebio",
        "linkedin": "https://www.linkedin.com/company/palisade-bio/"
    },
    "investor_relations": "https://investors.palisadebio.com",
    "key_executives": [
        {
            "name": "Tom Hallam",
            "position": "CEO"
        },
        {
            "name": "Jason J. S. W. W. Lee",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PB2452"
            ]
        }
    ],
    "seo": {
        "meta_title": "Palisade Bio, Inc. | Innovative GI Therapeutics",
        "meta_description": "Explore Palisade Bio, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal diseases. Learn about our pipeline and commitment to patient care.",
        "keywords": [
            "Palisade Bio",
            "Biopharmaceuticals",
            "Gastrointestinal Diseases",
            "PB2452",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Palisade Bio known for?",
            "answer": "Palisade Bio is known for developing innovative therapies for gastrointestinal diseases, particularly its lead product candidate PB2452."
        },
        {
            "question": "Who is the CEO of Palisade Bio?",
            "answer": "Tom Hallam is the CEO of Palisade Bio, Inc."
        },
        {
            "question": "Where is Palisade Bio headquartered?",
            "answer": "Palisade Bio is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Palisade Bio's main products?",
            "answer": "Palisade Bio's main product candidate is PB2452, aimed at mitigating the effects of anticoagulants."
        },
        {
            "question": "When was Palisade Bio founded?",
            "answer": "Palisade Bio was founded in 2020."
        }
    ],
    "competitors": [
        "RLYB",
        "CRBP",
        "SRNE"
    ],
    "related_stocks": [
        "VRTX",
        "AMGN",
        "GILD",
        "BMY"
    ]
}